Biodexa Pharmaceuticals Plc (NASDAQ:BDRX - Get Free Report) was the target of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 47,000 shares, an increase of 1,368.8% from the January 31st total of 3,200 shares. Based on an average daily trading volume, of 512,200 shares, the days-to-cover ratio is currently 0.1 days.
Biodexa Pharmaceuticals Stock Performance
NASDAQ:BDRX traded down $0.38 on Monday, hitting $2.95. The stock had a trading volume of 78,819 shares, compared to its average volume of 241,813. The business has a 50-day moving average price of $4.23. Biodexa Pharmaceuticals has a 52-week low of $2.92 and a 52-week high of $74.00.
Biodexa Pharmaceuticals Company Profile
(
Get Free Report)
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Recommended Stories
Before you consider Biodexa Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodexa Pharmaceuticals wasn't on the list.
While Biodexa Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
